Catheter ablation for the treatment of paroxysmal supraventricular tachycardia.
Radiofrequency catheter ablation has evolved into a front-line curative therapy for patients who have paroxysmal supraventricular tachycardia secondary to Wolff-Parkinson-White syndrome. AV nodal reentrant tachycardia, and atrial tachycardia. In patients with accessory pathways, cure rates exceed 90% in almost all anatomic locations. Equally high success rates are noted in patients with atriofascicular pathways and the permanent form of junctional reciprocating tachycardia. Complications secondary to catheter ablation of accessory pathways occur in 1% to 3% of patients and include cardiac perforation, tamponade, AV block, and stroke. In patients with AV modal reentrant tachycardia, selective slow pathway ablation is curative in over 95% of patients with a very low risk of AV block. Atrial tachycardias originating in both the left and right atria can be successfully ablated in over 80% of patients. Given the overall effectiveness of this procedure, radiofrequency catheter ablation should be considered as front-line therapy in patients with recurrent or drug-refractory paroxysmal supraventricular tachycardia. Although an effective therapy, the risks and benefits of this procedure need to be assessed in all patients who are candidates for this procedure.
Electrophysiology Laboratory, University of Texas Medical School at Houston, USA.
G V
GV
Naccarelli
H T
HT
Shih
S
S
Jalal
D016275:Atrial Function; D001283:Atrioventricular Node / Q000503:physiopathology; D017115:Catheter Ablation; D006329:Heart Conduction System / Q000601:surgery; D006801:Humans; D011183:Postoperative Complications; D013610:Tachycardia / Q000209:etiology / Q000601:surgery; D013611:Tachycardia, Atrioventricular Nodal Reentry / Q000601:surgery; D013614:Tachycardia, Paroxysmal / Q000503:physiopathology / Q000601:surgery*; D013617:Tachycardia, Supraventricular / Q000503:physiopathology / Q000601:surgery*